Pfiz­er dumps a fad­ing pipeline star, giv­ing up on its PC­SK9 drug bo­co­cizum­ab

Paul M. Rid­ker, MD, SPIRE clin­i­cal tri­als pro­gram

You can scratch any hopes you might have had that Pfiz­er could mount a come-from-be­hind win and seize the lead from Am­gen and Sanofi/Re­gen­eron in the race of PC­SK9 cho­les­terol drugs. The phar­ma gi­ant has de­cid­ed to drop its can­di­date, bo­co­cizum­ab, cit­ing wan­ing ef­fi­ca­cy re­sults, a poor mar­ket re­cep­tion for the pi­o­neers, signs of an im­mune re­sponse to the drug and side ef­fects that would have like­ly marred its de­but.

Pfiz­er will now slam the brakes on two late-stage stud­ies — Spire-1 and Spire-2 — de­signed to test their drug in 32,000 pa­tients, a mas­sive­ly ex­pen­sive en­deav­or that went look­ing for the kinds of out­comes da­ta that could win over pay­ers. And it’s tak­ing a $0.04 R&D charge on the move.

Pfiz­er’s shares dropped 2.2% on the de­ci­sion in pre-mar­ket trad­ing Tues­day.

The move marks the ter­mi­na­tion of one of the phar­ma gi­ant’s biggest late-stage clin­i­cal ef­forts, leav­ing it still in the hunt for new drugs that can whip up some en­thu­si­asm from an­a­lysts.

Am­gen and Sanofi/Re­gen­eron sparked big hopes for their fran­chise plays in this field, bat­tling each oth­er for first-mover po­si­tion and vow­ing to jump out in front in the strug­gle to seize a mar­ket worth bil­lions. So far, though, the com­pa­nies have been bru­tal­ly dis­ap­point­ed by the ane­mic ini­tial de­mand for these ther­a­pies, as pay­ers kick back on the cost. That soft launch com­bined with ev­i­dence that Pfiz­er’s drug may not have mea­sured up well, ev­i­dent­ly played a key role in the de­ci­sion to kill it af­ter spend­ing hun­dreds of mil­lions of dol­lars on de­vel­op­ment.

Bar­clays dis­cussed it with Pfiz­er ex­ecs, and came away with this con­clu­sion:

Of note, the de­ci­sion to dis­con­tin­ue bo­co­cizum­ab was not in­flu­enced by any on­go­ing out­comes da­ta or feed­back from the da­ta mon­i­tor­ing com­mit­tee; the tri­als are still blind­ed. In our view, the cul­prit was the pres­ence of an­ti-drug an­ti­bod­ies (ADAs). Of note, from the pub­lished phase 2 da­ta from bo­co­cizum­ab, the ADA rate was ~7%.  It seemed to us that the pres­ence of ADAs in some pa­tients on bo­co­cizum­ab be­came prob­lem­at­ic, with a mi­nor­i­ty of pa­tients hav­ing a ‘sub­stan­tial lev­el’ of ADAs and a larg­er num­ber hav­ing a high­er back­ground lev­el. In our view, this like­ly wouldn’t have af­fect­ed the over­all prob­a­bil­i­ty of suc­cess in the SPIRE-1 or SPIRE-2, but it would present chal­lenges com­mer­cial­ly, where Am­gen’s Repatha or Re­gen­eron’s Pralu­ent haven’t seen an ADA rate in that range. And it does ex­plain an at­ten­u­a­tion of LDL-C ef­fect with bo­co­cizum­ab.

Pfiz­er had al­ready read out da­ta from the first 4 of 6 stud­ies in the late-stage pro­gram, reg­u­lar­ly tout­ing its ef­fi­ca­cy and pro­mot­ing its mar­ket­ing hopes in the field. Now The Med­i­cines Com­pa­ny, part­nered with Al­ny­lam, will move up to the third spot in this race with a PC­SK9 drug that a may on­ly need twice-year­ly dos­ing.

Pfiz­er has one of the weak­est late-stage pipelines in Big Phar­ma, and this set­back was not­ed by sev­er­al an­a­lysts, in­clud­ing Leerink’s Sea­mus Fer­nan­dez, who said: “This re­moves an im­por­tant Ph3 pipeline prod­uct for PFE while elim­i­nat­ing a ma­jor pot’l com­peti­tor for AMGN (MP) and SNY/REGN.”

Aside from the new­ly ac­quired PARP ta­la­zoparib, the check­point in­hibitor avelum­ab part­nered with Mer­ck KGaA and the SGLT2 di­a­betes drug er­tugliflozin part­nered with Mer­ck, Pfiz­er doesn’t have much that’s new in late-stage stud­ies. Much of its Phase III ef­fort is now giv­en to biosim­i­lars.

Pfiz­er promised to hus­tle out the da­ta on its de­funct PC­SK9 drug for fur­ther dis­cus­sion.

“To hon­or the al­tru­ism of tri­al par­tic­i­pants, and to max­i­mize the clin­i­cal and sci­en­tif­ic knowl­edge de­rived from the halt­ed tri­als, Pfiz­er has com­mit­ted to en­sur­ing that the da­ta will be made avail­able to study lead­ers for in­de­pen­dent analy­sis and prompt pub­lic pre­sen­ta­tion. We be­lieve the avail­able da­ta will al­low us to test the core sci­en­tif­ic ques­tions posed by the over­all pro­gram which is in the best in­ter­est of pa­tients who vol­un­teered in these clin­i­cal tri­als, and for pa­tients world­wide who suf­fer from heart dis­ease,” stat­ed Paul M. Rid­ker, MD, Co-chair Ex­ec­u­tive Com­mit­tee, SPIRE clin­i­cal tri­als pro­gram and di­rec­tor for Car­dio­vas­cu­lar Dis­ease Pre­ven­tion, Brigham and Women’s Hos­pi­tal.

In­side Track: Be­hind the Scenes of a Ma­jor Biotech SPAC

Dr. David Hung and Michelle Doig are no strangers to the SPAC phenomenon. As Founder and CEO of Nuvation Bio, a biotech company tackling some of the greatest unmet needs in oncology, Dr. Hung recently took the company public in one of this year’s biggest SPAC related deals. And as Partner at Omega Funds, Doig not only led and syndicated Nuvation Bio’s Series A, but is now also President of the newly formed, Omega-sponsored, Omega Alpha SPAC (Nasdaq: OMEG; oversubscribed $138m IPO priced January 6, 2021).

Hal Barron, GSK R&D chief (Endpoints News)

Hal Bar­ron gam­bles $625M cash on high-wire TIG­IT act, throw­ing Glax­o­SmithK­line in­to heat­ed race and com­plet­ing next-gen I/O trin­i­ty

Count Hal Barron and GlaxoSmithKline in for the TIGIT fight.

The stakes are as high as the risks: While a growing pack of Big Pharma rivals is lending credence to the hypothesis that TIGIT will be the next big immune checkpoint and cancer drug target, the first clinical trials have shown response rates that can be described as modest at best. But Barron’s bet is on the whole “axis” that the receptor sits on, with an eye on testing its new anti-TIGIT antibody not just in combo with PD-1 but also in triplets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

As Covid-19 shifts the world's at­ten­tion to biotech, Noubar Afeyan's Flag­ship builds $3.4B fund to fu­el new in­ven­tions. Here's the plan

A little more than a year ago, Flagship Pioneering rolled out a monster fund with $1.1 billion in it to bankroll the platform companies they were creating inside their own labs. But it turns out, that was just the prelude to a much, much larger raise, as both current investors — who’ve been reaping the rewards of some booming biotech stocks — join in with new investors betting on more in the years to come.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bio­gen sig­nals a big PhI­II fail­ure as the lead gene ther­a­py in their $800M Night­star buy­out goes down in flames

That $800 million buyout of Nightstar has turned into a bust for Biogen as the lead therapy in the deal failed a pivotal study, signaling a severe setback for the biotech’s ambitions in gene therapies.

The big biotech put out the word after the market closed on Monday that the gene therapy they picked up in the deal for a degenerative blindness called choroideremia failed the Phase III study, just a month after their #2 drug in the deal also flopped in a mid-stage study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

Geoffrey Porges, SVB Leerink

Top an­a­lyst maps a rocky road for Ver­tex — un­less they adopt a $10B M&A cam­paign to save the pipeline

After repeatedly poking Vertex $VRTX execs with pointed criticism of their R&D strategy, top SVB Leerink analyst Geoffrey Porges is now turning up the heat to a full-scale roasting.

In a note out early Monday morning, Porges spotlights the impact of Vertex’s recent follow-up failure on AATD — their treatment hit the endpoint but missed on commercial prospects — rewriting his recommended scenario for CEO Reshma Kewalramani as she grapples with the setback.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

Stephen Hahn (AP Images)

UP­DAT­ED: Ex-FDA com­mish Stephen Hahn joins Flag­ship, a ven­ture group that spawned Covid-19 vac­cine mak­er Mod­er­na

That revolving door between the FDA and industry is spinning even faster than usual.

Former FDA commissioner Stephen Hahn is joining Flagship Pioneering, the venture outfit that founded Moderna — which raced its way to an FDA EUA for a Covid-19 vaccine that is making billions of dollars– as the new CMO of its Preemptive Medicine and Health Security initiative.

Flagship confirmed the hire — first reported in The Washington Post — in a statement out late Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.

Patrizia Cavazzoni, CDER

FDA’s Cavaz­zoni calls for ad­comms to ‘get back to the sub­stance’

While her comments were recorded prior to the FDA’s recent approval of Biogen’s controversial Alzheimer’s drug, CDER Director Patrizia Cavazzoni presciently called for substantiating reforms to the advisory committee process at the agency.

Short on examples, Cavazzoni said at a BIO event aired on Monday that some recent adcomms show “how they can be swayed by emotion in the face of hard facts,” but they need to “get back to the fundamentals, which is listening to thoughtful input from experts in response to thoughtful questions that we ask them.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Terns Phar­ma­ceu­ti­cals touts safe­ty da­ta from an ex-Eli Lil­ly can­di­date in the hunt for NASH treat­ment

While many others have tried — and failed — to get a NASH candidate across the finish line, Terns Pharmaceuticals thinks its FXR agonist will eventually earn its wings without the safety issues that have slowed others down. Now, a mid-stage safety readout could help add some validity to those hopes.

No patients in the Phase IIa LIFT study discontinued TERN-101 due to side effects, CMO Erin Quirk said during a call with investors on Monday morning. That includes pruritus, an uncomfortable itching sensation that frequently leads patients to drop out of other FXR agonist studies.

Paul Burton, incoming Moderna CMO (J&J/file photo)

Look­ing be­yond the pan­dem­ic, Mod­er­na ap­points J&J vet­er­an Paul Bur­ton as new CMO

Moderna is turning to one of its Covid-19 vaccine competitors to fill its open CMO slot, but this time, it’s not the vaccine experience they’re after.

Paul Burton, who’s spent 16 years at J&J, most recently as chief global medical affairs officer of Janssen, will take over as Moderna CMO on July 6.

With an eye toward a future beyond the pandemic, the mRNA biotech went with Burton, who earned his MD and PhD degrees in London, as he offers experience on a range of therapeutic areas, as well as work as a cardiothoracic surgeon and leading tech projects with Apple.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,300+ biopharma pros reading Endpoints daily — and it's free.